Immunotech Biopharm Past Earnings Performance
Past criteria checks 0/6
Immunotech Biopharm's earnings have been declining at an average annual rate of -13%, while the Biotechs industry saw earnings growing at 11.7% annually.
Key information
-13.0%
Earnings growth rate
-7.6%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | n/a |
| Return on equity | -196.3% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Immunotech Biopharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -335 | 53 | 177 |
| 30 Sep 23 | 0 | -315 | 65 | 164 |
| 30 Jun 23 | 0 | -296 | 76 | 150 |
| 31 Mar 23 | 0 | -307 | 87 | 163 |
| 31 Dec 22 | 0 | -318 | 98 | 176 |
| 30 Sep 22 | 0 | -333 | 103 | 205 |
| 30 Jun 22 | 0 | -347 | 108 | 233 |
| 31 Mar 22 | 0 | -351 | 106 | 237 |
| 31 Dec 21 | 0 | -354 | 104 | 241 |
| 30 Sep 21 | 0 | -383 | 94 | 266 |
| 30 Jun 21 | 0 | -412 | 84 | 291 |
| 31 Mar 21 | 0 | -426 | 76 | 285 |
| 31 Dec 20 | 0 | -439 | 69 | 279 |
| 30 Sep 20 | 0 | -336 | 56 | 206 |
| 30 Jun 20 | 0 | -232 | 43 | 134 |
| 31 Mar 20 | 0 | -171 | 36 | 98 |
| 31 Dec 19 | 0 | -109 | 28 | 62 |
Quality Earnings: 6978 is currently unprofitable.
Growing Profit Margin: 6978 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6978 is unprofitable, and losses have increased over the past 5 years at a rate of 13% per year.
Accelerating Growth: Unable to compare 6978's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6978 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).
Return on Equity
High ROE: 6978 has a negative Return on Equity (-196.31%), as it is currently unprofitable.